Paradigm Capital Management Inc. NY continued to hold its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Paradigm Capital Management Inc. NY’s holdings in Halozyme Therapeutics were worth $128,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Alliancebernstein L.P. grew its holdings in shares of Halozyme Therapeutics by 4.4% during the second quarter. Alliancebernstein L.P. now owns 176,694 shares of the biopharmaceutical company’s stock worth $2,265,000 after purchasing an additional 7,500 shares during the last quarter. Atlantic Trust Group LLC lifted its stake in shares of Halozyme Therapeutics by 6.5% in the second quarter. Atlantic Trust Group LLC now owns 26,625 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 1,615 shares during the period. Synovus Financial Corp lifted its stake in shares of Halozyme Therapeutics by 41.5% in the second quarter. Synovus Financial Corp now owns 36,156 shares of the biopharmaceutical company’s stock worth $463,000 after acquiring an additional 10,596 shares during the period. Swiss National Bank lifted its stake in shares of Halozyme Therapeutics by 14.4% in the second quarter. Swiss National Bank now owns 206,500 shares of the biopharmaceutical company’s stock worth $2,647,000 after acquiring an additional 26,000 shares during the period. Finally, Pacad Investment Ltd. lifted its stake in shares of Halozyme Therapeutics by 254.6% in the second quarter. Pacad Investment Ltd. now owns 65,887 shares of the biopharmaceutical company’s stock worth $845,000 after acquiring an additional 47,304 shares during the period. Institutional investors own 85.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/14/halozyme-therapeutics-inc-halo-stake-maintained-by-paradigm-capital-management-inc-ny.html.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened at 13.18 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $15.20. The firm has a 50-day moving average price of $12.63 and a 200 day moving average price of $13.19. The firm’s market capitalization is $1.77 billion.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.21) EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post ($0.97) earnings per share for the current fiscal year.

A number of equities analysts recently commented on the company. BidaskClub lowered Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Friday, August 11th. Canaccord Genuity set a $16.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Jefferies Group LLC reaffirmed an “underperform” rating and issued a $7.00 price objective (up from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday, August 10th. Finally, ValuEngine raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Halozyme Therapeutics presently has an average rating of “Hold” and a consensus target price of $14.75.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.